Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 108

1.

Mevalonate kinase deficiency: disclosing the role of mevalonate pathway modulation in inflammation.

Marcuzzi A, Crovella S, Monasta L, Vecchi Brumatti L, Gattorno M, Frenkel J.

Curr Pharm Des. 2012;18(35):5746-52. Review.

PMID:
22726114
2.

Specific increase in caspase-1 activity and secretion of IL-1 family cytokines: a putative link between mevalonate kinase deficiency and inflammation.

Normand S, Massonnet B, Delwail A, Favot L, Cuisset L, Grateau G, Morel F, Silvain C, Lecron JC.

Eur Cytokine Netw. 2009 Sep;20(3):101-7. doi: 10.1684/ecn.2009.0163. Review.

3.

Temperature and drug treatments in mevalonate kinase deficiency: an ex vivo study.

Tricarico PM, Kleiner G, Piscianz E, Zanin V, Monasta L, Crovella S, Marcuzzi A.

Biomed Res Int. 2013;2013:715465. doi: 10.1155/2013/715465. Epub 2013 Sep 1.

4.

Hyper-IgD syndrome or mevalonate kinase deficiency.

Stoffels M, Simon A.

Curr Opin Rheumatol. 2011 Sep;23(5):419-23. doi: 10.1097/BOR.0b013e328349c3b1. Review.

PMID:
21760510
5.

Mevalonate kinase deficiency, a metabolic autoinflammatory disease.

van der Burgh R, Ter Haar NM, Boes ML, Frenkel J.

Clin Immunol. 2013 Jun;147(3):197-206. doi: 10.1016/j.clim.2012.09.011. Epub 2012 Oct 4. Review.

PMID:
23110805
6.

Geraniol rescues inflammation in cellular and animal models of mevalonate kinase deficiency.

Marcuzzi A, Crovella S, Pontillo A.

In Vivo. 2011 Jan-Feb;25(1):87-92.

PMID:
21282739
7.

Targeting farnesyl-transferase as a novel therapeutic strategy for mevalonate kinase deficiency: in vitro and in vivo approaches.

De Leo L, Marcuzzi A, Decorti G, Tommasini A, Crovella S, Pontillo A.

Pharmacol Res. 2010 Jun;61(6):506-10. doi: 10.1016/j.phrs.2010.02.012. Epub 2010 Mar 3.

PMID:
20206266
8.

The inhibition of mevalonate pathway induces upregulation of NALP3 expression: new insight in the pathogenesis of mevalonate kinase deficiency.

Pontillo A, Paoluzzi E, Crovella S.

Eur J Hum Genet. 2010 Jul;18(7):844-7. doi: 10.1038/ejhg.2010.9. Epub 2010 Feb 24.

9.

Natural isoprenoids are able to reduce inflammation in a mouse model of mevalonate kinase deficiency.

Marcuzzi A, Pontillo A, De Leo L, Tommasini A, Decorti G, Not T, Ventura A.

Pediatr Res. 2008 Aug;64(2):177-82. doi: 10.1203/PDR.0b013e3181761870.

PMID:
18391837
10.

The farnesyltransferase inhibitors tipifarnib and lonafarnib inhibit cytokines secretion in a cellular model of mevalonate kinase deficiency.

Marcuzzi A, De Leo L, Decorti G, Crovella S, Tommasini A, Pontillo A.

Pediatr Res. 2011 Jul;70(1):78-82. doi: 10.1203/PDR.0b013e31821b581c.

PMID:
21430599
11.

Block of the mevalonate pathway triggers oxidative and inflammatory molecular mechanisms modulated by exogenous isoprenoid compounds.

Tricarico PM, Kleiner G, Valencic E, Campisciano G, Girardelli M, Crovella S, Knowles A, Marcuzzi A.

Int J Mol Sci. 2014 Apr 22;15(4):6843-56. doi: 10.3390/ijms15046843.

12.

Autoinflammatory syndromes.

Hashkes PJ, Toker O.

Pediatr Clin North Am. 2012 Apr;59(2):447-70. doi: 10.1016/j.pcl.2012.03.005. Review.

PMID:
22560579
13.

The effect of clodronate on a mevalonate kinase deficiency cellular model.

Zanin V, Marcuzzi A, Piscianz E, Vuch J, Bianco AM, Monasta L, Decorti G, Crovella S.

Inflamm Res. 2012 Dec;61(12):1363-7. doi: 10.1007/s00011-012-0537-4. Epub 2012 Aug 1.

PMID:
22851203
14.

Microglia activation and interaction with neuronal cells in a biochemical model of mevalonate kinase deficiency.

Tricarico PM, Piscianz E, Monasta L, Kleiner G, Crovella S, Marcuzzi A.

Apoptosis. 2015 Aug;20(8):1048-55. doi: 10.1007/s10495-015-1139-8.

PMID:
26003816
15.

Mevalonate kinase deficiency in two sisters with therapeutic response to anakinra: case report and review of the literature.

Campanilho-Marques R, Brogan PA.

Clin Rheumatol. 2014 Nov;33(11):1681-4. doi: 10.1007/s10067-014-2523-4. Epub 2014 Feb 15. Review.

PMID:
24531849
16.

Alendronate, a double-edged sword acting in the mevalonate pathway.

Tricarico PM, Girardelli M, Kleiner G, Knowles A, Valencic E, Crovella S, Marcuzzi A.

Mol Med Rep. 2015 Sep;12(3):4238-42. doi: 10.3892/mmr.2015.3957. Epub 2015 Jun 18.

17.

Mevalonate Pathway Blockade, Mitochondrial Dysfunction and Autophagy: A Possible Link.

Tricarico PM, Crovella S, Celsi F.

Int J Mol Sci. 2015 Jul 15;16(7):16067-84. doi: 10.3390/ijms160716067. Review.

18.

Rare hereditary autoinflammatory disorders: towards an understanding of critical in vivo inflammatory pathways.

Kanazawa N.

J Dermatol Sci. 2012 Jun;66(3):183-9. doi: 10.1016/j.jdermsci.2012.01.004. Epub 2012 Jan 18. Review.

PMID:
22336993
19.

Mevalonate kinase deficiency and neuroinflammation: balance between apoptosis and pyroptosis.

Tricarico PM, Marcuzzi A, Piscianz E, Monasta L, Crovella S, Kleiner G.

Int J Mol Sci. 2013 Nov 26;14(12):23274-88. doi: 10.3390/ijms141223274. Review.

20.

[Hereditary periodical fever syndromes].

Herlin T, Sørensen N, Veirum J.

Ugeskr Laeger. 2011 Mar 28;173(13):968-73. Review. Danish.

PMID:
21453638

Supplemental Content

Support Center